CTOs on the Move

Parrish Medical Center

www.parrishmed.com

 
Parrish Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Parrish Medical Center is based in Titusville, FL. You can find more information on Parrish Medical Center at www.parrishmed.com
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

City of Winston-Salem, NC

City of Winston-Salem, North Carolina, U.S.A. Local government. Contact City Link call 311; citylink@cityofws.org

iRhythm

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Nolato Group

Nolato Group is a Baldwin, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iowa Health Syst Poison Cntrl

Iowa Health Syst Poison Cntrl is a Sioux City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.